What is the curative effect and function of Ranvartinib?

Ranvartinib is the third generation targeted anti-angiogenesis drug, which is mainly used for the treatment of primary liver cancer. At present, Ranvartinib is widely used in clinic because the second-line treatment after sorafenib progress or the first-line treatment of primary liver cancer can further prolong the progression-free survival and overall survival of patients compared with sorafenib.

Ranvartinib can achieve anti-tumor effect mainly by blocking vascular endothelial growth factor receptor, and at the same time, it can inhibit tumor angiogenesis and block tumor nutrient supply, thus playing a therapeutic role. The common side effects of Ranvartinib include nausea, vomiting, diarrhea, liver function damage and renal function damage.

Because the efficacy and safety of Ranvartinib have been well verified, it has become one of the first-line drugs for treating patients with primary liver cancer in clinic, and it has also been listed in the national medical insurance catalogue.